Citigroup Inc Cellectis S.A. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	BUY	$1.85 - $2.6 $18 - $26	10 Added 3.95%	263 $0
Q3 2022 Nov 10, 2022	SELL	$2.29 - $4.08 $162 - $289	-71 Reduced 21.91%	253 $1,000
Q2 2022 Aug 10, 2022	SELL	$2.39 - $4.93 $84,663 - $174,640	-35,424 Reduced 99.09%	324 $1,000
Q1 2022 May 12, 2022	SELL	$3.45 - $8.77 $26,875 - $68,318	-7,790 Reduced 17.89%	35,748 $162,000
Q4 2021 Feb 10, 2022	SELL	$8.01 - $12.84 $80,059 - $128,335	-9,995 Reduced 18.67%	43,538 $354,000
Q3 2021 Nov 10, 2021	BUY	$11.94 - $16.09 $639,184 - $861,345	53,533 New	53,533 $675,000

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.